Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Rami S. Komrokji MD and Jamile Shammo MD FASCP FACP review data from key MDS and MPN presentations at the 2016 American Society of Hematology Annual Meeting.

Share

Program Content

Activities

  • NIVO or IPI ± AZA in MDS
    Nivolumab or Ipilimumab ± Azacitidine in Treatment-Naive or HMA-Failed Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • MPD-RC 112: PegIFN α-2a vs HU in PV/ET
    MPD-RC 112: Frontline Peginterferon α-2a vs Hydroxyurea in High-Risk Polycythemia Vera and Essential Thrombocythemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • Ropeginterferon α-2b vs HU in PV
    Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen